title: Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen.
abstract: Recent updates of the guidelines on the prevention of human immunodeficiency virus mother-to-child transmission have shortened the neonatal zidovudine prophylactic regimens from 6 to 4 weeks. We present a prospective observational study in a large cohort of mother-infant pairs and report that the 4-week regimen allows an earlier recovery of the anemia in these otherwise healthy infants.
authors: Department of Pediatrics, Pediatric Infectious Diseases Unit, Hospital Sant Joan de Déu-Universitat de Barcelona, Barcelona, Spain.
authors: Rebeca
authors: R
authors: Lahoz
authors: Antoni
authors: A
authors: Noguera
authors: Núria
authors: N
authors: Rovira
authors: Albert
authors: A
authors: Català
authors: Emília
authors: E
authors: Sánchez
authors: Rafael
authors: R
authors: Jiménez
authors: Clàudia
authors: C
authors: Fortuny
mesh_terms: D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D018890:Chemoprevention; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine